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H ypertensive disorders of pregnancy (HDPs),  including preeclampsia,  occur in up to 10% of 
pregnancies.  Preeclampsia is a complication that is 
involved in maternal and neonatal morbidity and mor-
tality and influences the perinatal prognosis.  The 
pathogenesis of preeclampsia has been described by the 
two-stage disorder theory proposed by Roberts et al.  
[1].  The onset of preeclampsia is thought to be related 
to an increase in hypoxia-induced factor-1α (HIF-1α) 
and increases in antiangiogenic factors such as soluble 
fms-like tyrosine kinase-1 (sFlt-1) [2 , 3] and soluble 
endoglin (sEng) [4 , 5].  The imbalance between these 
antiangiogenic and angiogenic factors is important in 
the onset of preeclampsia,  but the pathogenesis of pre-
eclampsia is not yet fully understood.
(Pro)renin is an inactive precursor of renin,  and by 
binding to the (pro)renin receptor [(P)RR],  (pro)renin 
acquires renin enzymatic activity non-proteolytically.  
The expression of (pro)renin has been confirmed in 
pregnancy-related tissues such as amniotic fluid,  villus,  
and placenta [6 , 7].  It was also reported that the blood 
(pro)renin concentration is higher in the umbilical cord 
vein than in the umbilical cord artery [8],  and that 
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An association between preeclampsia and (pro)renin was recently reported.  Intracellular signaling of the (pro)
renin receptor [(P)RR] increases the expressions of TGF-β and PAI-1.  In this study we sought to clarify the 
involvement of (pro)renin in the pathogenesis of preeclampsia via the intracellular signaling of (P)RR on pre-
eclampsia placentas.  Activated (pro)renin plasma concentrations were compared between pregnant women 
with (n = 15) and without (n = 28) preeclampsia.  The placentas were immunohistochemically evaluated with 
anti-HIF-1α and anti-(P)RR antibodies.  HTR-8/SVneo cells were cultured under hypoxic conditions and 
treated with human recombinant (pro)renin.  The mRNA expressions of HIF-1α,  (P)RR,  PAI-1,  TGF-β,  and 
ET-1 were also examined by real-time RCR.  The activated (pro)renin plasma concentration was significantly 
higher in the third vs.  the second trimester in the preeclampsia patients.  HIF-1α and (P)RR expressions were 
significantly increased in the preeclampsia placentas.  The mRNA expressions of PAI-1,  TGF-β,  and ET-1 were 
significantly increased in the experiments using recombinant (pro)renin vs.  hypoxic conditions.  (P)RR expres-
sion in preeclampsia placentas is increased by persistent hypoxia through the second and third trimesters,  and 
PAI-1,  TGF-β,  and ET-1 production is increased via (P)RR.  Our results suggest that ET-1 production via the 
intracellular signaling of (P)RR is important in the pathogenesis of preeclampsia.
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(pro)renin is produced in trophoblastic cells during 
pregnancy [9].
An association between preeclampsia and (pro)
renin was reported.  Namely,  pregnant women with 
type 1 diabetes and a high concentration of (pro)renin 
in early pregnancy were shown to be likely to develop 
preeclampsia [10].  In addition,  the (pro)renin placen-
tal concentration in women with preeclampsia is sig-
nificantly higher than that in normotensive pregnant 
women.  However,  a previous study reported a lower 
(pro)renin concentration in women with preeclampsia 
[11],  while  another study found no significant differ-
ence in the (pro)renin concentration between women 
with preeclampsia and those with normal pregnancies 
[12].  The role of the (pro)renin concentration in pre-
eclampsia thus remains unclear.
In this study,  we compared the (pro)renin concen-
tration between women with preeclampsia and healthy 
pregnant women.  We immunostained preeclampsia 
and normal-pregnancy placentas with anti-(P)RR anti-
body and compared the difference in the placental 
expression of (P)RR.  We also sought to clarify the 
involvement of (pro)renin in the pathogenesis of pre-
eclampsia via (P)RR-mediated intracellular signaling in 
the human trophoblast cell line HTR-8/SVneo.
Materials and Methods
Measurement of the activated (pro)renin concen-
tration by ELISA. The subjects were 15 women with 
preeclampsia and 28 with a normal pregnancy.  Maternal 
plasma samples of the pregnant women who had their 
delivery at Okayama University Hospital between June 
2017 and April 2018 were obtained from routine blood 
testing at the second and third trimesters.  Activated 
(pro)renin concentrations in maternal plasma samples 
were measured using an enzyme-linked immunosor-
bent assay (ELISA) kit (Yanaihara Institute,  Shizuoka,  
Japan) according to the manufacturer’s instructions.  
Samples were assayed in duplicate,  and the mean was 
calculated.  Results were compared between the women 
with preeclampsia and the women with normal preg-
nancies.  Preeclampsia was defined based on the guide-
lines from the American College of Obstetricians and 
Gynecologists.  The study was approved by the Ethics 
Committee of Okayama University Graduate School of 
Medicine,  Dentistry,  and Pharmaceutical Sciences and 
Okayama University Hospital (No. Ken1705-020).
Immunohistochemistry. The human placental 
tissues of women with preeclampsia and women with 
normal pregnancies were analyzed by immunohisto-
chemistry.  Anti-HIF-1α (Proteintech,  Chicago,  IL,  
USA) and anti-(P)RR (Sigma Aldrich,  St. Louis,  MO,  
USA) antibodies were used.  Briefly,  4-μm-thick paraf-
fin sections from each specimen were mounted on glass 
slides and dried overnight at 37°C.  All sections were 
deparaffinized in two baths of xylene for 10 min and 
then rehydrated by sequential incubation with 100%,  
95%,  80%,  and 60% ethanol for 5 min in each bath.  
The sections were quenched for endogenous peroxidase 
activity in 0.3% H2O2 for 10 min and processed for anti-
gen retrieval by boiling in citrate buffer (pH 6.0) for 
20 min in a 98°C water bath.
The sections were incubated with rabbit anti-HIF-1α 
(dilution 1 : 100; Proteintech) and rabbit anti-(P)RR 
(dilution 1 : 200; Sigma Aldrich) polyclonal primary 
antibodies at room temperature for 60 min.  Then,  the 
sections were incubated with secondary antibodies 
labeled with anti-rabbit horseradish peroxidase polymer 
(Dako,  Glostrup,  Denmark) for 30 min.  Diamino-
benzidine substrate was used as the chromogen for 
2 min,  and dark brown staining was considered posi-
tive.  The sections were then counterstained with hema-
toxylin and observed under a light microscope.
Cell culture. The HTR-8/SVneo cell line 
(American Type Culture Collection,  Manassas,  VA,  
USA) was derived by transfecting the cells that grew out 
of chorionic villi explants of human first-trimester pla-
centa.  HTR-8/SVneo cells were cultured in RPMI-1640 
(Sigma Aldrich,  St. Louis,  MO,  USA) containing 5% 
fetal bovine serum and 1% penicillin/streptomycin/
amphotericin B (all from Gibco BRL,  Grand Island,  
NY,  USA).  The cells were cultured under an atmo-
sphere of humidified 5% CO2 at 37°C for 24 h (control),  
or exposed to 5% O2 hypoxic conditions using a 
BIONIX hypoxic cell culture kit (Sugiyamgen,  Tokyo,  
Japan) [13 , 14],  or treated with human recombinant 
(pro)renin (10 ng/ml; Cayman Chemical,  Ann Arbor,  
MI,  USA) [(pro)renin group].
Real-time RT-PCR. For the real-time reverse 
transcriptase polymerase chain reaction (RT-PCR),  
total RNA (10 μg) was reverse transcribed in 20 μL of 
reaction solution according to the protocol of a high-ca-
pacity cDNA reverse transcription kit (Applied 
Biosystems,  Foster City,  CA,  USA).  The amplification 
of HIF-1α,  (P)RR (encoded by the gene ATP6AP2),  
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plasminogen activator inhibitor-1 (PAI-1),  transform-
ing growth factor-beta (TGF-β),  endothelin-1 (ET-1),  
and β-actin genes was performed.  β-actin was used as 
an internal control.  The expression of these genes was 
detected by using gene-specific TaqMan primers/probes 
(HIF-1α: Hs00153153_m1; ATP6AP2: Hs00997145_
m1; PAI-1: Hs00167155_m1; TGF-β: Hs00998133_
m1; ET-1: Hs00174961_m1; β-actin: Hs99999903_
m1; Thermo Fisher Scientific,  Waltham,  MA,  USA).  
The amplification was performed on a STEP ONE PCR 
system (Applied Biosystems) with initial denaturation 
at 95°C for 15 s,  followed by 50 cycles of annealing at 
60°C with a final extension at 60°C for 1 min.  The real-
time PCR results were obtained by the comparative CT 
method.
Measurement of ET-1 by ELISA. Maternal plasma 
samples were obtained from routine blood testing at the 
third trimester.  Serum ET-1 concentrations were mea-
sured using an ELISA kit (R&D Systems,  Minneapolis,  
MN,  USA) according to the manufacturer’s instruc-
tions.  Samples were assayed in duplicate,  and the mean 
was calculated.  Results were compared between the 
pregnant women who developed an HDP and the 
women with normal pregnancies.
Data analysis. The real-time PCR data are 
expressed as the mean ± SEM.  The data analysis was 
performed using the Software Package for Social 
Sciences (IBM,  Armonk,  NY,  USA).  The Mann-
Whitney U-test and χ2 test were used to examine the 
between-group differences in concentrations and gene 
expressions.  Differences were considered significant at 
p < 0.05.
Results
Activated (pro)renin concentration in maternal 
blood. The maternal characteristics of the study par-
ticipants are summarized in Table 1.  In the preeclamp-
sia group (n = 15),  the subjects’ age and body mass 
index were significantly higher and weeks of delivery,  
birth weight,  and placental weight were significantly 
lower (p < 0.05).  The activated (pro)renin concentration 
in preeclampsia was significantly lower in the second 
trimester of pregnancy: 994.8 pg/ml (541.2-2,026.3 pg/
ml) in the normal pregnancy vs. 599.4 pg/ml (330.6-
896.6 pg/ml) in the preeclampsia group (Fig. 1A).  This 
difference was not significant in the third trimester:  
837.6 pg/ml (479.4-2,166.3 pg/ml) in the normal preg-
nancy vs. 717.0 pg/ml (660.4-1,018.1 pg/ml) in the pre-
eclampsia group (Fig. 1B).
There was no significant difference in the activated 
(pro)renin concentrations of the normal pregnancy 
group between trimesters: first trimester vs. second 
trimester vs. third trimester,  1,225.6 pg/ml (735.5-
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????? ?　 Maternal characteristics of normal pregnancies and pregnancies with preeclampsia
Normal pregnancies
(n=28)
Preeclampsia
(n=15) p-value
Age (years)＊ 34.0 (23-44) 39.0 (30-43) p＜0.05
Times of pregnancy＊＊
　Primigravida 20 (71.4%) 7 (46.7%) N.S.
　Multigravida 8 (28.6%) 8 (53.3%)
BMI (kg/m2)＊ 20.4 (17.3-32.5) 23.7 (18.2-34.1) p＜0.05
Onset
　Early onset (＜34 week) 7 (46.7%)
　Late onset (≧34 week) 8 (53.3%)
Weeks of delivery (week)＊ 38.5 (36-41) 35.0 (29-40) p＜0.05
Infantʼs sex＊＊
　male 12 (42.8%) 6 (40.0%) N.S.
　female 16 (57.2%) 9 (60.0%)
Birth weight (g)＊ 3,040 (2,346-3,720) 2,576 (1,040-3,972) p＜0.05
Placental weight (g)＊ 567 (470-870) 447.5 (258-839) p＜0.05
Methods of delivery＊＊
　Vaginal delivery 16 (57.1%) 6 (40.0%) N.S.
　Caesarean section 12 (42.9%) 9 (60.0%)
Data are median (range).　　＊Mann-Whitney U test, ＊＊χ2 test
1,613.0 pg/ml) vs. 994.8 pg/ml (541.2-2,026.3 pg/ml) 
vs. 837.6 pg/ml (479.4-2,166.3 pg/ml) (Fig.1C).  However,  
the activated (pro)renin concentrations were signifi-
cantly higher in the third trimester than in the second 
trimester in the preeclampsia group: second trimester 
vs. third trimester,  599.4 pg/ml (330.6-896.6 pg/ml) vs. 
436 ????????????? ????????? ????????????? ???? ???? ??
2,500
2,000
1,500
1,000
500
0
2,500
2,000
1,500
1,000
500
0
2,500
2,000
1,500
1,000
500
0
2,500
2,000
1,500
1,000
500
0
P<0.01
P<0.05
A, Second trimester
C, Normal pregnancy
B, Third trimester
(p
ro
)re
ni
n 
co
nc
en
tra
tio
n pg/ml
(p
ro
)re
ni
n 
co
nc
en
tra
tio
n pg/ml
Normal pregnancy
1st trimester 2nd trimester 3rd trimester
D, Preeclampsia
(p
ro
)re
ni
n 
co
nc
en
tra
tio
n pg/ml
2nd trimester 3rd trimester
Preeclampsia
(p
ro
)re
ni
n 
co
nc
en
tra
tio
n pg/ml
Normal pregnancy Preeclampsia
N.S.
N.S.
N.S. N.S.
HIF-1αA
(P)RRC (P)RRD
HIF-1αB
???? ?　 Immunohistochemical staining of HIF-1α and (P)RR at 400× magniﬁcation.  Positive staining is shown in brown (black arrow).  
A,  Immunohistochemical staining of HIF-1α in preeclampsia placentas; B,  Immunohistochemical staining of HIF-1α in normal pregnancy 
placentas; C,  Immunohistochemical staining of (P)RR in preeclampsia placentas; D,  Immunohistochemical staining of (P)RR in normal 
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the second and third trimester between 
the normal pregnancies and pree-
clampsia pregnancies; □,  Normal 
pregnancy; ■,  Preeclampsia preg-
nancy; C,D,  Comparison of acti-
vated (pro)renin concentration 
between the normal pregnancies and 
preeclampsia pregnancies in each 
trimester; □,  Normal pregnancy; ■,  
Preeclampsia pregnancy.  ＊p＜0.05.
717.0 pg/ml (660.4-1,018.1 pg/ml) (Fig. 1D).
Immunohistochemical staining of HIF-1α and (P)
RR in human placental tissues. Preeclampsia pla-
centas are hypoxic,  and we thus performed immuno-
histochemical staining for HIF-1α in human placental 
tissues.  To confirm that the expression of (P)RR is 
increased under hypoxic conditions,  we also performed 
the immunohistochemical staining of (P)RR.
The expression of HIF-1α was increased in the pre-
eclampsia placentas (Fig. 2A) compared to that in the 
women with normal pregnancies (Fig. 2B).  The expres-
sion of (P)RR was also increased in the preeclampsia 
placentas (Fig. 2C) compared to that in the women with 
normal pregnancies (Fig. 2D).  The proportion of a 
moderate-to-strong expression of (P)RR was signifi-
cantly higher in the preeclampsia placentas: women 
with normal pregnancies vs. women with preeclampsia,  
2/12 (16.7%) vs. 13/17 (76.4%).
The mRNA expressions of HIF-1α, (P)RR, PAI-1, 
TGF-β, and ET-1 in HTR-8/SVneo cells under hypoxic 
conditions. We performed experiments using 
HTR-8/SVneo cells to investigate the role of intracellu-
lar signaling via (P)RR.  The mRNA expressions of all 
targets were significantly higher in the hypoxic condi-
tions than in the controls cultured for 24 h (Fig. 3).  The 
control value in this experiment was set to 1,  and the 
value of hypoxic conditions was calculated as the ratio 
to the control value.
The mRNA expressions of PAI-1, TGF-β, and ET-1 
in HTR-8/SVneo cells treated with human recombi-
nant (pro)renin under hypoxic conditions. The 
mRNA expressions of all targets were significantly 
higher in the (pro)renin group than in the hypoxic con-
ditions cultured for 24 h (Fig. 4A-C).  The hypoxic con-
dition value in this experiment was set to 1,  and the 
value of the (pro)renin group was calculated as the ratio 
to the hypoxic condition value.
ET-1 concentration in maternal blood. To deter-
mine whether ET-1 is also elevated in vivo,  we measured 
the ET-1 concentration in maternal blood.  In the third 
trimester of pregnancy,  the ET-1 concentration in the 
preeclampsia group at 1.30 pg/ml (0.16-2.78 pg/ml) was 
significantly higher than that in the women with normal 
pregnancies at 0.66 pg/ml (0.23-1.48 pg/ml) (Fig. 5).
Discussion
In preeclampsia,  the vascular resistance of the 
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maternal uterine spiral artery does not decrease due to 
inadequate remodeling in the early stage of pregnancy,  
and this hypoxic condition persists in preeclampsia pla-
centas [15].  As a result of persistent hypoxia due to 
placental blood flow disturbance,  the preeclampsia 
placenta becomes hypoplastic [16 , 17].  In the present 
study,  the activated (pro)renin concentration in the 
preeclampsia patients was significantly lower than in the 
women with normal pregnancies in the second trimes-
ter.  However,  we observed the opposite results in the 
third trimester.  Compared to the production in women 
with normal pregnancies,  the production of activated 
(pro)renin in the preeclampsia placenta is reduced 
because of placental hypoplasia.  However,  as the 
hypoxia condition persists in preeclampsia,  the expres-
sions of HIF-1α and (P)RR in the placenta are 
increased,  and thus the activated (pro)renin concentra-
tion in maternal blood is increased in the third trimes-
ter.  It has been reported that the expressions of HIF-1α 
[18] and (P)RR [19] are increased in the preeclampsia 
placenta.  In our present study,  immunohistochemistry 
was performed on the human placental tissue using 
anti-HIF-1α and anti-(P)RR antibodies.  Both expres-
sions were increased in the women with preeclampsia 
compared to the women with normal pregnancies.
We also examined the involvement of the pathogen-
esis of preeclampsia via (P)RR-mediated intracellular 
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signaling in the human trophoblast HTR-8/SVneo cell 
line,  and we observed that the mRNA expressions of 
HIF-1α,  (P)RR,  PAI-1,  TGF-β,  and ET-1 were signifi-
cantly increased in the HTR-8/SVneo cells under 
hypoxic conditions.  Moreover,  the mRNA expressions 
of PAI-1,  TGF-β,  and ET-1 were significantly increased 
in the HTR-8/SVneo cells treated with human recombi-
nant (pro)renin under hypoxic conditions.  It has been 
reported that the expression of (P)RR is increased in 
chorionic cells under hypoxic conditions [19].  We 
obtained similar results in the hypoxic HTR-8/SVneo 
cell cultures in this study.
(P)RR-mediated intracellular signaling has been 
shown to activate mitogen-activated protein kinase and 
extracellular signal-regulated kinase 1/2 [20-23],  and it 
was observed that the expressions of PAI-1 and TGF-β 
are increased through their intracellular signaling 
[24 , 25].  TGF-β is a cytokine that causes the produc-
tion of ET-1; in the present study,  the ET-1 production 
in HTR-8/SVneo cells increased.  ET-1 is a potent vaso-
constrictor,  and a relationship between ET-1 and pre-
eclampsia has been described in recent years [26-29].  
The ET-1 maternal plasma level is increased in pre-
eclampsia [26].  ET-1 has been reported to correlate 
with antiangiogenic factors such as sFlt-1,  and it has 
been considered to play an important role in the patho-
genesis of preeclampsia [27].  By the binding of (pro)
renin to (P)RR in chorionic cells,  the production of 
PAI-1 and TGF-β increases through intracellular signal-
ing.  As a result,  the production of ET-1 increases,  and 
this increase is thought to contribute to the onset of 
hypertension in preeclampsia.
The activated (pro)renin concentration during preg-
nancy depends on the placenta,  and its concentration 
in the second trimester in preeclampsia is low due to 
placental hypoplasia.  However,  the expression of (P)
RR is increased by the persistence of hypoxia due to 
uteroplacental circulation failure,  and the activated 
(pro)renin concentration is increased in the third tri-
mester.  An increased expression of (P)RR in the pla-
centa of preeclampsia activates intracellular signaling 
via (P)RR,  resulting in increased productions of PAI 
and TGF-β.  The production of ET-1 consequently 
increases,  and it has been speculated that this increase 
contributes to the development of hypertension.  Our 
present analyses revealed a relationship between the 
(pro)renin concentration during pregnancy in pre-
eclampsia and the expression of (P)RR in the placenta.  
This report is also the first to clarify the importance of 
the production of ET-1 via the intracellular signaling of 
placental (P)RR in the pathogenesis of preeclampsia.
As a study limitation,  we did not investigate the 
relation between (pro)renin and antiangiogenic factors 
and angiogenic factors,  and it is unclear how much 
ET-1 is involved in hypertension in preeclampsia.  
Further studies in vivo are required to determine 
whether suppressing the production of ET-1 inhibits 
hypertension.
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